Tocagen Inc.

Chiron Corporation

Gensia Pharmaceuticals, Inc.

University of California

Other

Denovo Biopharma LLC

Gensia, Inc.

Intervu, Inc.

Kintera, Inc.

Akamai Technologies, Inc.

Metabasis Therapeutics, Inc.

Chiron Viagene, Inc.

Gensia Sicor Inc.

Harry E Gruber

Douglas J Jolly

Paul K Laikind

Jack R Barber

James G Respess

Christopher R Logg

Clinton E Browne

Omar D Perez

Bheemarao G Ugarkar

Kay Olmstead

Brian Kenner

Mark D Erion

Ephraim Feig

Amy Lin

Paul J Marangos

Kevin M Mullane

Derek G Ostertag

Joan M Robbins

David A Bullough

Julie Schwartz

Sunil D Chada

Angelo J Castellino

Leonard P Miller

Daniel C St Louis

John F Warner

Hwei-Sing Kwang

Tiffany Huang

Jack W Reich

Srinivas Rao Kasibhatla

Ronald R Tuttle

Brett C Bookser

Noriyuki Kasahara

Carlos E Ibanez

Stephen M W Chang

Ernest K Metzner

Stephen M Chang

Gary S Firestein

Ryan Burnett

Ernest K Metzker

Bheemaro G Vgarkar

Amy H Lin

The disclosure provides vectors for treating cancers, method of producing such vectors and methods of use of the vectors.

Retroviral vector having immune-stimulating activity

The disclosure provides an extended release formulation of 5-fluorocytosine. In another aspect, a method of treating a fungal disease is provided. The method comprises administering to a subject in need thereof a fungus-treating effective amount of a composition comprising 5-fluorocytosine. In yet another aspect, a method of treating a cancer is provided. The method comprises administering to a subject in need thereof a sufficient amount of an expression vector to induce expression of cytosine deaminase which is capable of converting 5-fluorocytosine to 5-fluorourcail in cells of the cancer and a cancer-treating effective amount of a composition comprising 5-fluorocytosine.

Formulations of 5-fluorocytosine and uses thereof

This disclosure provides a retroviral replicating vector for gene delivery comprising a therapeutic cassette containing at least one mini-promoter linked to a gene to be expressed.

Retroviral vector with mini-promoter cassette

The disclosure provides an extended release formulation of 5-fluorocytosine. In another aspect, a method of treating a fungal disease is provided. The method comprises administering to a subject in need thereof a fungus-treating effective amount of a composition comprising 5-fluorocytosine. In yet another aspect, a method of treating a cancer is provided. The method comprises administering to a subject in need thereof a sufficient amount of an expression vector to induce expression of cytosine deaminase which is capable of converting 5-fluorocytosine to 5-fluorouracil in cells of the cancer and a cancer-treating effective amount of a composition comprising 5-fluorocytosine.

This disclosure provides modified cytosine deaminases (CDs). The disclosure further relates to cells and vector expressing or comprising such modified CDs and methods of using such modified CDs in the treatment of disease and disorders.

Recombinant vectors

Gene therapy vectors and cytosine deaminases

This disclosure relates to replication competent viral vectors for treating cell proliferative disorders. The disclosure further relates to the use of such replication competent viral vectors for delivery and expression of a heterologous nucleic acid in normal and diseased tissues and methods and compositions that facilitate such delivery and expression to tissues in vivo and in vitro. The disclosure further relates to replication competent retroviral vectors for these uses and in conjunction with methods and compositions that facilitate in vivo therapeutics.

Compositions comprising gamma retrovirus vectors and methods of treating proliferative disorders

This disclosure relates to a combination therapy of chemotherapeutics and/or radiosensitizing agents with a replication competent viral vectors for treating cell proliferative disorders and chemotherapeutic treatments. The disclosure further relates to the use of such replication competent viral vectors for delivery and expression of a heterologous nucleic acid in normal and diseased tissues and methods and compositions that facilitate such delivery and expression to tissues in vivo and in vitro. The disclosure further relates to replication competent retroviral vectors for these uses and in conjunction with methods and compositions that facilitate in vivo therapeutics.

Cancer combination therapy and recombinant vectors

This disclosure provides recombinant replication competent retroviral vectors having increased stability. The disclosure further relates compositions and uses of such vectors in the treatment of disease and disorders.

A web-based mission certification quiz for educating various persons involved in a fundraising campaign is disclosed. A web-based method for educating solicitors, donors, participants and others involved in a fundraising campaign about the campaign's mission includes providing, on a website, information about the campaign's mission, taking, on the website, a mission certification quiz by answering one or more questions, wherein the questions are designed to test a participant's knowledge about the campaign's mission. The method further includes determining a final score based on the number of correct answers, and creating a mission certificate on the website based on the final score.

Mission certification quiz for fundraising campaign

Growing community of inventors

Rancho Santa Fe, CA, United States of America

Harry E Gruber